Patents by Inventor Zhaoxing Chu

Zhaoxing Chu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF
    Publication number: 20230140276
    Abstract: The present invention provides a tricyclic compound, its preparation method and medical use. The tricyclic compound is a compound having the structure of the following formula (I), and its pharmaceutically acceptable salt, prodrug, tautomer, stereoisomers or mixtures of stereoisomers. The compound of the present invention has significant activity of antagonizing histamine H1 receptor, and has lower anti-M-choline side effects and lower hERG toxicity, Wherein the group is defined as described in the specification.
    Type: Application
    Filed: April 27, 2021
    Publication date: May 4, 2023
    Inventors: Guangwei HE, Zhaoxing CHU, Qinlong XU, Jiajia MO, Gaofeng LIN, Yan ZHAO, Li SHAO
  • PARP/PI3K double-target inhibit containing pyridopyrimidine structure
    Patent number: 11572359
    Abstract: The present disclosure relates to the field of pharmaceutical chemistry, in particular to a class of PARP/PI3K double-target inhibitors (I) containing structures of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine and phthalazin-1(2H)-one and a preparation method thereof. As proved by pharmacodynamic tests, the compounds of the present disclosure have PARP/PI3K double-target inhibitory activity and can be used for anti-tumor.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: February 7, 2023
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Yungen Xu, Qihua Zhu, Junwei Wang, Hui Li, Zhaoxing Chu, Guangwei He
  • Compound pharmaceutical composition for treating skin inflammatory diseases
    Patent number: 11318151
    Abstract: The disclosure relates to the field of pharmaceutical technology, in particular, to a compound pharmaceutical composition for treating skin inflammatory diseases, which is characterized in that an active ingredient of the compound pharmaceutical of the disclosure is composed of tofacitinib and crisaborole, and the composition has a stronger therapeutic effect and a lower dosage with a significant synergistic therapeutic effect. The pharmaceutical composition of the disclosure can be used to treat skin inflammatory diseases.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 3, 2022
    Assignees: HEFEI INDUSTRIAL PHARMACEUTICAL INSTITUTE CO., LTD, HEFEI AMVITE PHARMACEUTICAL CO., LTD
    Inventors: Guangwei He, Zhaoxing Chu, Qinlong Xu, Jiajia Mo, Yan Zhao, Lincui Bian, Yuanfeng Gu, Li Shao
  • Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof
    Patent number: 11161860
    Abstract: The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.
    Type: Grant
    Filed: December 25, 2018
    Date of Patent: November 2, 2021
    Assignees: HEFEI INDUSTRIAL PHARMACEUTICAL INSTITUTE CO., LTD, HEFEI AMVITE PHARMACEUTICAL CO., LTD.
    Inventors: Guangwei He, Zhaoxing Chu, Qinlong Xu, Feng Li, Weizhong Liu, Jiajia Mo, Yan Zhao
  • PARP/PI3K DOUBLE-TARGET INHIBITOR CONTAINING PYRIDOPYRIMIDINE STRUCTURE
    Publication number: 20210179610
    Abstract: The present disclosure relates to the field of pharmaceutical chemistry, in particular to a class of PARP/PI3K double-target inhibitors (I) containing structures of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine and phthalazin-1(2H)-one and a preparation method thereof. As proved by pharmacodynamic tests, the compounds of the present disclosure have PARP/PI3K double-target inhibitory activity and can be used for anti-tumor.
    Type: Application
    Filed: August 1, 2018
    Publication date: June 17, 2021
    Inventors: Yungen XU, Qihua ZHU, Junwei WANG, Hui LI, Zhaoxing CHU, Guangwei HE
  • COMPOUND HAVING EFFECTS OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
    Publication number: 20210179640
    Abstract: The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.
    Type: Application
    Filed: December 25, 2018
    Publication date: June 17, 2021
    Inventors: Guangwei He, Zhaoxing Chu, Qinlong Xu, Feng Li, Weizhong Liu, Jiajia Mo, Yan Zhao
  • COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING SKIN INFLAMMATORY DISEASES
    Publication number: 20200352965
    Abstract: The disclosure relates to the field of pharmaceutical technology, in particular, to a compound pharmaceutical composition for treating skin inflammatory diseases, which is characterized in that an active ingredient of the compound pharmaceutical of the disclosure is composed of tofacitinib and crisaborole, and the composition has a stronger therapeutic effect and a lower dosage with a significant synergistic therapeutic effect. The pharmaceutical composition of the disclosure can be used to treat skin inflammatory diseases.
    Type: Application
    Filed: May 9, 2019
    Publication date: November 12, 2020
    Inventors: Guangwei He, Zhaoxing Chu, Qinlong Xu, Jiajia Mo, Yan Zhao, Lincui Bian, Yuanfeng Gu, Li Shao